Mike Biotech: Net profit in the first half of the year was 34.0425 million yuan, a year-on-year decrease of 83.12%.

Mike Bio disclosed its 2025 interim report on the evening of July 31st, reporting an operating income of 1.075 billion yuan in the first half of the year, a decrease of 15.94% year-on-year; a net profit attributable to the parent company of 34.0425 million yuan, a decrease of 83.12% year-on-year; and a basic earnings per share of 0.06 yuan. The main factors leading to the change in performance are the significant changes in the company's revenue structure due to the divestiture of agency business in recent years and the strengthening of the self-owned product distribution system; the introduction of various industry policies has intensified competition in the domestic in vitro diagnostic market, leading to a decrease in the market size of some routine testing projects due to a simultaneous decrease in quantity and price, resulting in a decrease in sales of self-owned products on various platforms of the company or a slowdown in growth during the reporting period.